Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rose 14.6% over 21 sessions and closed at the assessment-period high. Q2 VYJUVEK revenue reached $119.2 million, while 94.6% gross margin, strong profitability, international launches, and second-half 2026 clinical readouts support continuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Exceptional Margins ⢠Strong Liquidity ⢠Low Leverage KRYS combines exceptional profitability, strong cash generation, ample liquidity, and minimal debt, but its elevated valuation and investment outflows warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Support Test ⢠Weak Momentum ⢠$350 Reclaim Support Level: $336â$337 Resistance Level: $347â$351, then $358â$371 KRYS is testing $336â$337 support amid weak momentum below its ~$350 average; a sustained move above $350 would improve the outlook, while a break below support signals further downside.
Sentiment & News
Key News Insights: ⢠Vyjuvek Growth ⢠Institutional Buying ⢠Pipeline Expansion Krystal Biotech's momentum is supported by Vyjuvek growth, pipeline expansion, and rising institutional ownership.
AI Summary
KRYS is a profitable, cash-rich VYJUVEK franchiseânot a typical cash-burning biotechâbut its premium valuation demands sustained U.S. growth, timely European launches, and validating pipeline data, making investors best served waiting for evidence of durable expansion rather than chasing recent strength.
Description
Krystal Biotech is a clinical-stage biotechnology company developing redosable gene therapies for serious, primarily rare, dermatologic and genetic conditions. Its lead candidate, beremagene geperpavec (B-VEC), is in Phase III for dystrophic epidermolysis bullosa, while a portfolio of other programs spans early- and preclinical development for congenital ichthyosis, netherton syndrome, cystic fibrosis and multiple dermatology indications including aesthetic applications. The company was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | KRYS | Krystal Biotech, Inc. | Rose 14.6% over 21 sessions and closed at the assessment-period high. Q2 VYJUVEK revenue reached $119.2 million, while 94.6% gross margin, strong profitability, international launches, and second-half 2026 clinical readouts support continuation. | Closed | -7.0% |
| Nov 3 | Nov 10 | KRYS | Krystal Biotech, Inc. | Selected as a speculative near-term buy ahead of Nov 3 earnings supported by FDA label expansion, upcoming European/Japanese launches, strong margins, and positive biotech sector trends, with cautious risk management due to seasonal sales softness and inventory build. | Closed | +0.9% |